C-IDDApartial reprogramming, senolytic polyphenols, longevity diagnostics
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
https://www.kimbino.ca/metro/?utm_source=reels 📢 NEW Metro catalogue on kimbino 🛒✨📅 Offers valid: Apr 16, 2026 - Apr 22, 2026 🗓️👀 Have you seen it yet? Don't miss out on amazing deals! 💰🛍️🔎 kimbino has the latest flyers from your favorite supermarkets! ✨💬 Tag your friends in the comments and spread the word by sharing this post! 🚀📣 #flyers #deals #discounts #offers #metro | Kimbino.ca
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
Undergraduate Research | Department of Biology Skip to main content Stanford University Stanford Department of Biology School of Humanities and Sciences Search Menu Home Academics Overview Undergraduate Program Toggle Undergraduate Program Advising Toggle Advising BioBridge Advising How to Declare Major Capstone Toggle Capstone Honors Program The Senior Reflection (TSR) Independent Capstone Out of Department Research Capstone FAQs Doing Research Toggle Doing Research Directed Reading Undergraduate Research Biology Summer Undergraduate Research Program (BSURP) Toggle Biology Summer Undergraduat … ome department subject code, e.g. MED 199. Once you declare the major, you will submit a BIO 199X petition and start enrolling under that subject code. You must submit your BIO 199X petition within one quarter of declaring the Biology major in order to receive credit toward your major electives . For Honors, only your BIO 199/X units count from your junior and senior years. Students only need to petition ONCE to work with the same sponsor. If you switch labs, you will b … ONCE to work with the same sponsor. If you switch labs, you will be required to submit a new petition. Appropriate Research Projects The research field is expected to encompass biological concepts and processes. Projects should be empirical or theoretical biological research, consisting of independent and original scientific work by the student. Applied clinical, environmental, or technological studies may be appropriate in cases where there is a major analytical, experimenta … appropriate. Petition Procedure To petition for BIO 199X credit , students must submit the following items to the Biology Form Submission website or in Gilbert 118: Complete the Petition Form Fill out the Petition and Research Sponsorship Form (Fillable) Write a Description of Your Research Your research proposal should be at least 2-3 pages in length (double spaced, not including references and figures) and should be organized as described below using the followi … aterial requires that you complete the Human Subjects Training. If any of these apply, describe them in your proposal. Possible results . Describe the expected outcome of your research, indicating how the data collected will be used to draw conclusions regarding the research question. Throughout your proposal, be specific about your own work: do
Client Challenge JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
BIO-BS Program | Stanford University Bulletin Skip to Main Content Stanford University Academic Calendar 2022-23 Schedule of Classes Bulletin Archive Get Help Stanford University Catalog Stanford University Home Programs Courses Student Policies BIO-BS - Biology (BS) Download as PDF Biology Undergraduate Matriculated BS - Bachelor of Science Overview Program Policies Learning Outcomes Program Overview The undergraduate major in Biology can serve as a stepping-stone for a wide variety of career opportunities. For students planning to attend medical, dental, or veterinary school, or graduate sch … or which the student has obtained prior approval. Administrative steps include: Submit an approved honors proposal to the department's student services office two quarters prior to graduation. For instance, students graduating Spring Quarter must submit petitions no later than Autumn Quarter of the same academic year. Complete at least 10 units of an approved research project in from the same lab. Students conducting research in a lab outside of the department of Biology must … Students conducting research in a lab outside of the department of Biology must submit an Out of Department Research Petition either before they start their research, or if research was started prior to declaring the Biology major, as soon as their major declaration is approved. Only research units from BIO or BIOHOPK are counted toward the 10 unit requirement. Obtain at least a 3.0 (B) grade point average (GPA) in all Biology major requirements taken at Stanford … sium, however their attendance is optional. Complete and, by the published deadline within the quarter graduation is expected, submit online an honors thesis approved by at least two readers. At least one reader must be from the faculty of the Department of Biology, and both readers must be Academic Council members. The title page of the honors thesis must include student name, thesis title, name and department of research sponsor, and name and department of second reade … nt of research sponsor, and name and department of second reader. Students must submit this page with original ink signatures to the student services office by the published deadline for the quarter in which graduation is expected. Further information on the honors program is available on the Honors Program and Undergraduate Research in Bio
%PDF-1.6 %���� 137 0 obj > endobj xref 137 32 0000000016 00000 n 0000001943 00000 n 0000002025 00000 n 0000002153 00000 n 0000002345 00000 n 0000002567 00000 n 0000003608 00000 n 0000004661 00000 n 0000004731 00000 n 0000004806 00000 n 0000004882 00000 n 0000006022 00000 n 0000007073 00000 n 0000007147 00000 n 0000008300 00000 n 0000008507 00000 n 0000009683 00000 n 0000009880 00000 n 0000011055 00000 n 0000025585 00000 n 0000042862 00000 n 0000043834 00000 n 0000098879 00000 n 0000099145 00000 n 0000146838 00000 n 0000147122 00000 n 0000199216 00000 n 0000199488 00000 n 0000217683 00000 n 000 … ��� *Yݖ�F�OH�q�g���kp6�����ͬ�T��e禢?~��m���G��-s�ꧦ���SY��ё��W��5��zk�K�rFp-�f�����`���'�R�j�`_�ߍ,U�k��"MpV�d�֖��>��%�M� Ɣ��n��4�Ӆ6���%i�~����0�qK� %/��m. h"�����$ڽ��G����PW�y6�@���_�D�{��ȏ,Dj�'��] �&��!��*� {��0ك�������z+�u�]p�~O�έ�B���5��p_�9$�S"�Z)� �&��`��UJJ�V�����O�ȆoD��DE����T]��0��� ���5�5���{4�%^��Wc�����E��^���:?ߥD G�ʔ�� ���b�y ,� x,Y�j�VkO���m;� J_�+�M��+I[����� �VC���6b m���l��� `'[�w ��@�`��x'5l��6(m� … 2009-02-22T17:34:16-05:00 2009-02-22T17:34:26-05:00 Adobe InDesign CS2 (4.0.5) application/pdf special cover.indd costa uuid:ef6c6725-0130-11de-a470-0017f2c45e03 uuid:f6608621-0130-11de-a470-0017f2c45e03 Acrobat Distiller 7.0.5 for Macintosh endstream endobj 136 0 obj > endobj xref 0 137 0000000000 65535 f 0000218484 00000 n 0000218722 00000 n 0000218912 00000 n 0000224931 00000 n 0000225169 00000 n 0000225359 00000 n 0000231828 00000 n 0000232066 00000 n 0000232256 00000 n
%PDF-1.7 %���� 1 0 obj >/Metadata 251 0 R/ViewerPreferences 252 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/Annots[ 22 0 R 23 0 R] /MediaBox[ 0 0 594.96 842.04] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��][w�8�~�9�x�#͑൧O���t����F�����-3�'�䑬t{~�V@ꆒht �"Y��*ċ�]1?������+�8/�c�+�'_������Ŀ�? ��eY��P�y��"����ϟ��1}�����g/~�BJ�����g��qh%�0 �D|���� S1^��Ř���_o�?�G� ���������]�����o�r}_�u��G=��?�����^��z��|*�RG �\mv8���Hm��k�q�Spg�x�4h��Kw�P%h�$����_��^ސ�K ��a�H�+�]�Öj���K� Yz�;� �9V>
Prestel and Partner Family Office Forum Dubai --> About Us How you can Attend The Team Prestel in the Media Events & Dates Future of Wealth UAE 4th - 5th DECEMBER 2024 --> Family Office Forum Cayman Islands OCTOBER 2025 End Cayman Islands --> Family Office Forum Istanbul 2nd - 3rd JUNE 2026 --> Family Office Forum London 2nd - 3rd JULY 2026 Family Office Forum Wiesbaden FFM 22. - 23. SEPTEMBER 2026 Family Office Forum New York 13th - 14th OCTOBER 2026 Family Office Forum Zurich 10th - 11th NOVEMBER 2026 Family Office Forum Riyadh 2nd - 3rd DECEMBER 2026 Family Office Forum Dubai 24th - 25th MA … es and know-how on best practice in Government and Investments: We welcome your application to join us. 2026 Agenda Attend Speak Partner The Dubai Family Office Event Introduction Programme Speakers Partners Register Venue Past Events Conference Archives 2024 Agenda 2023 Conference Report --> Theme for 10th Edition was: Family Growth and Stability In the 10th year of the Family Office Forum Dubai, we honour 2026 — which the UAE’s President declared the “Year of the Famil … s no automatic right to join or sponsor , even if you are willing to pay. Every application is reviewed individually to ensure the Forum remains a safe and productive environment for Family Offices, with only a limited number of provider experts in attendance. Join us: Attend Speak Partner To see the 2025 detailed post event report, please click here . Welcoming Leading Wealth Creators, Family Members, Family Office Executives, Innovators and Experts Set over two days & desig … ose providing services or investment opportunities, on which the following fees apply. £4,490 Full delegate pass (24th- 25th March 2027) £2,990 One-day only delegate pass (24th OR 25th March 2027). Simply Email [email protected] Or apply below As a Single Family Office or Wealth Owner As a Solution Provider For General Information and our Terms and Conditions - click here . ** Our definition of a genuine Principal or Family Office us at least US$ 1 … e lines. He also founded and led their MENA family enterprise and family office award-winning consulting practice which specialises in assisting successful families, entrepreneurs, and family offices across MENA at managing risks, preserving and growing wealth. Ismael has contributed to building and is currently serving multiple Family Offices. H
If you find vskill useful, give it a star on GitHub → vskill Login / ⌘K Skills Studio Watch Submit Publishers Trust Queue Docs Insights vskill Securing the AI skills supply chain. Skills Studio Watch Publishers Trust Docs Queue Submit Insights GitHub npm SpecWeave MIT License Skill Studio — Local Skill Marketplace for AI Agents << Back to skill ── deep-research — Security Report Skill deep-research Publisher 199-biotechnologies Repository 199-biotechnologies / claude-deep-research-skill → Overall PASS Scanned by vskill platform — 52 built-in patterns + 3 external SAST tools (semgrep, njs
List of biotech, pharma & medical device company acquisitions About Directory Promoted Listings Purchase Data Drug Pipelines Data Licensing Weekly Update Newsletter Contact 0 Acquired Biotech Companies 159 Solutions Acquired by IQVIA, May 2018 23andMe Acquired by nonprofit, Jul 2025; Bankruptcy, Mar 2025 2seventy Bio Acquired by BMS, May 2025, $286M; bluebird bio spinout 3-Dimensional Pharmaceuticals Acquired by J&J, Jan 2003, $88M 3Clinical Research Acquired by Parexel, Mar 2004 3F Therapeutics Acquired by ATS Medical, Jan 2006 4-Antibody
nemotron-asr-mlx/LICENSE at main · 199-biotechnologies/nemotron-asr-mlx · GitHub Skip to content Navigation Menu Toggle navigation Sign in Appearance settings Platform AI CODE CREATION GitHub Copilot Write better code with AI GitHub Copilot app Direct agents from issue to merge MCP Registry New Integrate external tools DEVELOPER WORKFLOWS Actions Automate any workflow Codespaces Instant dev environments Issues Plan and track work Code Review Manage code changes APPLICATION SECURITY GitHub Advanced Security Find and fix vulnerabilities Code security Secure your code as you build Secret protecti … Trust center Partners View all resources Open Source COMMUNITY GitHub Sponsors Fund open source developers PROGRAMS Security Lab Maintainer Community Accelerator GitHub Stars Archive Program REPOSITORIES Topics Trending Collections Enterprise ENTERPRISE SOLUTIONS Enterprise platform AI-powered developer platform AVAILABLE ADD-ONS GitHub Advanced Security Enterprise-grade security features Copilot for Business Enterprise-grade AI features Premium Support Enterprise-grade 24/7 … our input very seriously. Include my email address so I can be contacted Cancel Submit feedback Saved searches Use saved searches to filter your results more quickly --> Name Query To see all available qualifiers, see our documentation . Cancel Create saved search Sign in Sign up Appearance settings Resetting focus You signed in with another tab or window. Reload to refresh your session. You signed out in another tab or window. Reload to refresh your session. You switched acc … e Work by the copyright owner or by an individual or Legal Entity authorized to submit on behalf of the copyright owner. For the purposes of this definition, "submitted" means any form of electronic, verbal, or written communication sent to the Licensor or its representatives, including but not limited to communication on electronic mailing lists, source code control systems, and issue tracking systems that are managed by, or on behalf of, the Licensor for the purpo … been received by the Licensor and subsequently incorporated within the Work. 2. Grant of Copyright License. Subject to the terms and conditions of this License, each Contributor hereby grants to You a perpetual, worldwide, non-exclusive, no-charge, royalty-free, irrevocable copyright license to reproduce, prepare Derivative Works of, publicly dis
‘Yamanaka factors are a biological cheat code’ Skip to content News Data Podcast Clinics News Data Podcast Clinics Search Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Advertise NEWSLETTER News Data Podcast Clinics News Data Podcast Clinics Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire About Contact About Contact Advertise nEWSLETTER Search Search TrimTech adds $14m in fundi... Winona study fi … r root. Longevity.Technology: In 2006, Professor Shinya Yamanaka made the Nobel Prize winning discovery that an adult cell could be reverted back into an embryonic stem cell by exposing them to a key group of protein transcription factors. Yamanaka’s groundbreaking work was just the beginning, as researchers across the world sought to harness the potential of transcription factors to reverse cellular aging via epigenetic reprogramming. 199 Bio is the latest company to enter a … e menopause symptoms simultaneously GARM Clinic launches first Klotho longevity residency in Roatan Cognito’s wearable device boosts brain proteins linked to Alzheimer’s protection Lys Therapeutics raises over $27m to advance new treatments for Parkinson’s and stroke RELATED ARTICLES Stem cell banking partnership targets future of longevity Rapalogix raises $20m for longevity skin health AbbVie expands blood cancer portfolio with recent FDA nod You might als
GitHub - 199-biotechnologies/claude-skill-seo-geo-optimizer: Production-ready Claude skill for comprehensive SEO/GEO optimization. Analyzes content for traditional search engines + AI platforms (ChatGPT, Perplexity, Claude, Gemini). Includes entity extraction, schema generation, and multi-format audit reports. · GitHub Skip to content Navigation Menu Toggle navigation Sign in Appearance settings Platform AI CODE CREATION GitHub Copilot Write better code with AI GitHub Copilot app Direct agents from issue to merge MCP Registry New Integrate external tools DEVELOPER WORKFLOWS Actions Automate an … ant dev environments Issues Plan and track work Code Review Manage code changes APPLICATION SECURITY GitHub Advanced Security Find and fix vulnerabilities Code security Secure your code as you build Secret protection Stop leaks before they start EXPLORE Why GitHub Documentation Blog Changelog Marketplace View all features Solutions BY COMPANY SIZE Enterprises Small and medium teams Startups Nonprofits BY USE CASE App Modernization DevSecOps DevOps CI/CD View all use cases BY … Trust center Partners View all resources Open Source COMMUNITY GitHub Sponsors Fund open source developers PROGRAMS Security Lab Maintainer Community Accelerator GitHub Stars Archive Program REPOSITORIES Topics Trending Collections Enterprise ENTERPRISE SOLUTIONS Enterprise platform AI-powered developer platform AVAILABLE ADD-ONS GitHub Advanced Security Enterprise-grade security features Copilot for Business Enterprise-grade AI features Premium Support Enterprise-grade 24/7 … our input very seriously. Include my email address so I can be contacted Cancel Submit feedback Saved searches Use saved searches to filter your results more quickly --> Name Query To see all available qualifiers, see our documentation . Cancel Create saved search Sign in Sign up Appearance settings Resetting focus You signed in with another tab or window. Reload to refresh your session. You signed out in another tab or window. Reload to refresh your session. You switched acc … python scripts/entity_extractor.py ~ /project/page.html Phase 2: Implementation Apply optimizations automatically: # Full optimization pipeline for specific platform python scripts/auto_implementer.py page.html perplexity # Individual optimization steps python scripts/content_optimizer.py page.html python scripts/platform_optimizer.py page.html c
199. Bio Bites: Doing Business in Boston - AUScelerate National » AUScelerate National 199. Bio Bites: Doing Business in Boston - AUScelerate National Home What we do Going Global Initiatives News Events Connect Careers Join our network Posted on: 04/08/2025 199. Bio Bites: Doing Business in Boston As the world’s largest biotech partnering event took place in Boston in June, MTPConnect was there introducing an Australian delegation to the Boston ecosystem, hosting business events to drive international collaborations and leading the Australian Pavilion to highlight Australia’s fast
199 Bio - 2026 Company Profile & Competitors - Tracxn JavaScript is disabled in your browser. enable it to enjoy the full features of Tracxn. Your browser was unable to load all of Tracxn resources. They may have been blocked by your firewall, proxy or browser configuration. Press Ctrl+F5 or Ctrl+Shift+R to have your browser try again and if that doesn't work, click here to retry or mail us at [email protected] Internal Server Error Toggle navigation Customers Investment Industry Venture Capital Funds Private Equity Funds Accelerators & Incubators Investment Banks Corporates and Start
EDGAR Filing Documents for 0001213900-21-057189 This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser. SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home » Company Search » Current Page Form 8-K - Current report: SEC Accession No. 0001213900-21-057189 Filing Date 2021-11-08 Accepted 2021-11-08 08:15:09 Documents 75 Period of Report 2021-11-08 Items Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of E
Contact Us - 199 Labs | By 199 Biotechnologies Let's discuss your manufacturing needs For partnership inquiries, custom compound synthesis, and bulk manufacturing requests Get in touch Direct Contact Email: [email protected] Headquarters & Main Laboratory 199 Gloucester Terrace London W2 6LD United Kingdom Partnership Opportunities We collaborate with research institutions, biotech companies, and healthcare providers worldwide to advance longevity science. Part of 199 Group 199 Labs is the manufacturing division of 199 Biotechnologies. See our full portfolio → Send Inquiry © 2025 199
Biotechnology, 39 Biotechnology, 39 (Terminated) Ticker: FWLNCX Distributions | Summary | Historical Pricing | Performance | Related Portfolios Date Public Offer Price Net Asset Value 12/20/2019 Not Avail $11.3898 12/19/2019 Not Avail $11.3230 12/18/2019 Not Avail $11.3090 12/17/2019 Not Avail $11.3684 12/16/2019 Not Avail $11.4182 12/13/2019 Not Avail $11.2750 12/12/2019 Not Avail $11.1384 12/11/2019 Not Avail $11.0650 12/10/2019 Not Avail $11.1628 12/9/2019 Not Avail $11.1252 12/6/2019 Not Avail $11.2033 12/5/2019 Not Avail $11.0854 12/4/2019 Not Avail $
A 13-Year Biotech Specialist Investor Census - RxDataLab RxDataLab Data Research About Data Research About Analysis Institutional Investors A 13-Year Biotech Specialist Investor Census A systematic institutional census of dedicated biotech investors. Analyzing SEC 13F filings to track 287 biotech-concentrated entities from 2013 through Q4 2025. June 22, 2026 Nicholas George Biotech is one of the most challenging industries for investors. Dominated by small-cap companies with capital intensive operations, binary catalysts, and a low probability of ever generating revenue, most would be wise to … ered, sitting at just 37 funds today. Biotech Specialist Lifecycles # Not every fund that qualifies as a specialist stays active. Of the 287 entities that have met the ≥60% specialist threshold, here is where they stood as of 2025 Q4: Status Count What happened Active specialist 148 Still meeting the ≥60% biotech threshold as of their most recent filing Below 60% threshold 37 Reported biotech share fell below 60% of reported 13F securities, but still filing 13Fs Below $100M t … threshold No recent filings 81 No 13F filed since early 2024. May indicate the fund closed, was acquired, or reorganized (e.g., Tekla Capital or Ghost Tree) Entry and exit patterns track the macro biotech cycle closely. 2020 was the peak entry year with 36 new funds crossing the specialist threshold, while 2024 marked the first year with net-negative fund growth (24 exits against 18 entrants). Tenure in the biotech specialist universe 287 funds that have ever met the ≥60% bi … sex Woodlands Management) is a PE/VC vehicle rather than a public-markets hedge fund and is excluded below. The eleven remaining funds that have been biotech specialists for nearly the entire study period and remain in the top Pure-Play tier (≥90% biotech) today: Baker Bros. Advisors BVF Partners Palo Alto Investors Sectoral Asset Management Tang Capital Management RA Capital Management Perceptive Advisors Redmile Group OrbiMed Advisors Cormorant Asset Management Great Point … d . Reach out to [email protected] with questions or comments! Interactive Fund Table The table below includes all 287 entities that have ever met the specialist threshold (≥60% biotech, >1 position, ≥$100M total equity), with their most recent filing data and lifecycle status. Search Tier All Pure-Play (≥90%) Focused (60–90%) Status All Act
Portfolio Home Strategies Overview Private Equity Structured Opportunities Public Equities Co-Investments Portfolio Team News Investor Login SEI Login MSFS Login Investor login SEI Login MSFS Login About Catalio Our Portfolio Investing in the next generation of life sciences Scroll ↓ [Portfolio] Companies We focus on life sciences companies developing next-generation drugs, devices and diagnostics, data, tools, and healthcare services and work closely with each portfolio company to build and grow the business from inception to exit. Strategy Strategy Private Equity Structured Opportunities C … ation by replying HELP. Message frequency varies and message and data rates may apply. You may review our Privacy Policy to learn how your data is used. Thank you! Your submission has been received! Something went wrong while submitting the form, please try again. Information Terms of Use Privacy Policy Security For Investors SEI Login MSFS Login Thank you! Submission received! Something went wrong, try again. ↑ Catalio Capital Management, LP | © 2026
Portfolio | Global Health Investment Corporation (GHIC) Skip Navigation Toggle Navigation About Portfolio Partners Programs News Careers Investment Portfolio GHIC supports innovation to improve global public health. Investing to Save Lives GHIC’s portfolio of technology companies and investment funds are developing and deploying diagnostics, vaccines, pharmaceuticals, and other medical products and have been catalytic in the launch of registered products that have reached more than 500 million people worldwide. Global Health Investment Fund Our namesake $108 million social impact fund (G … cs targeting diseases such as HIV/AIDS, malaria, tuberculosis, and cholera. The fund's portfolio companies have successfully commercialized more than a dozen products that have been delivered to over 500 million people. Read more about GHIF Global Health Security Fund In partnership with the Biomedical Advanced Research and Development Authority (BARDA), GHIC uses venture capital investments to accelerate the development and commercialization of technologies that respond to o … d middle-income countries through investments in funds and companies as well as grant making opportunities. Read more about CHIP Portfolio Investments Access Bio Global Health Investment Fund Intervention: Diagnostic Aerska Global Health Security Fund Intervention: Brain-targeted medicine delivery platform Alydia Health Global Health Investment Fund Intervention: Device Antheia Global Health Security Fund Intervention: Biosynthesis Manufacturing Platform Apriori Bio GLOBAL HE … vention: Biosynthesis Manufacturing Platform Apriori Bio GLOBAL HEALTH SECURITY Fund Intervention: Predictive vaccine design platform Atomo Diagnostics Global Health Investment Fund Intervention: Diagnostic BD Global Health Investment Fund Intervention: Diagnostic Biolinq Global Health Security Fund Intervention: Device BugSeq Bioinformatics Global Health Security Fund Intervention: Bioinformatics platform Centivax Global Health Security Fund Intervention: Vaccine platf … urity Fund Intervention: Vaccine platform Cytovale GLOBAL HEALTH SECURITY Fund Intervention: Cellular host response diagnostic Endpoint Health Global Health Security Fund Intervention: Therapeutic + Companion Diagnostic Monod Bio Global Health Security Fund Intervention: Diagnostic EUBiologics Global Health Investment Fund Intervention: Vac
ABM-Investors ABM-Investors About Us R&D Overview --> Overview Mission Management Investors R&D Strategy R&D Overview --> R&D Pipeline AACR Posters Expanded Access Partnership Investors News Contact Language Chinese /skin/images/seach.jpg" > --> About Us R&D Strategy R&D Strategy R&D Overview --> R&D Pipeline Expanded Access Partnership Investors News Contact Us 中 / EN English / 中文 --> Investors Investors China Growth Capital (CGC) description, 300) ?>... --> China Growth Capital (CGC) is a China-focused seed and early venture investor since 2006. The firm funds seed to Series B in enterprise … estments in innovative drugs & high-end medical devices as well as intelligence application & equipment. Portfolio companies include Kangtai (SHE 300601), Hybribio (SHE 300639), Shenogen, Ribo, Genfleet, Apollomics, Passiontec, Ycloset，Chipanaloc, etc. company : http://www.panlincap.com Viva Biotech description, 300) ?>... --> Viva Biotech（1873.HK）’s mission is to become a cradle for innovative biotechnology companies around the world. The Group provides structure-based drug … d in 2010, Delta Capital is a leading early-growth and growth equity investment fund platform in China. Delta Capital, centering on early growth equity investment, emphasizes on the value-investment approach to achieve the optimal balance between risk and return to maximize the investment results for LPs while maintaining strong risk control. Delta Capital has stable and highly experienced team over fifteen professionals, who leverage the firm's extensive operating and invest … tal.cn/ About Hermed Capital description, 300) ?>... --> Hermed Capital is a VC fund specialized in biopharmaceutical investments, mainly in the fields of innovative drugs and biotechnologies, with a focus on early and growth stage companies. The team has deep industrial backgrounds, extensive industrial and financial resources as well as successful experience in incubating and helping portfolio companies to become industrial leaders, team's portfolio include Henlius (2696.HK … h a total of more than 700 million US dollars in the three phases of the US/RMB fund. Baidu Venture Capital focuses on the early pioneer companies of emerging technologies and commits itself on several major directions such as commercial consumption, medical care and people's livelihood, as well as technology extension. Relying on the strong supp
Life Sciences - ICG Clients Who we are What we do Sustainability People News & insights Shareholders & Debtholders Menu Careers Client Lounge Contact us Intralinks Subscribe Search We invest globally. We grow businesses sustainably. We value partnerships. Who we are Overview Our purpose & business Our offices Asia Pacific Europe Middle East North America Our history Leadership & governance Annual reports Board & committees Executive directors Policies & disclosures Sustainability reports Our values Corporate social responsibility We invest globally. We grow businesses respo … t - Building long-term partnerships between pension schemes and private capital fund managers', at the BVCA's conference, Accelerate: Angel Investors, Venture & Growth Equity 22 May 2024 Website 2024 24 Apr 2024 Head of Life Sciences Dr Allan Marchington takes part in panel entitled 'What does a good deal look like & what Investors (really) want' at BioTrinity in London 24 Apr 2024 Website 2024 18 Apr 2024 Head of Life Sciences Dr Allan Marchington takes part in panel discuss
Client Challenge JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.
EDGAR Entity Landing Page EDGAR | Company Search Results Disabled --> FAQ EDGAR search tools Feedback Classic version Home » Company Search This company's Exchange Act registration has been revoked This company's Exchange Act registration as a Municipal Advisor has been revoked This company's Exchange Act registration as a Municipal Advisor has been cancelled Investor toolkit: On [+] Company Information CIK: EIN: LEI: SIC: (CF Office: ) State location: State of incorporation: Fiscal year end: Business address: Phone: Mailing address: Category: Filings: EDGAR filings since Get insider transacti
199 Biotechnologies - Engineering Human Longevity | Founded by Boris Djordjevic Skip to main content Home Programs Investors Company Contact Donate Home Company Company About 199 Bio We are the reprogramming company: rewriting malignant and senescent cell behavior and measuring outcomes with real‑time diagnostics. Mission Make disease biology legible and reversible. We build therapies that reprogram malignant and senescent cell states while using diagnostics to verify change. Team & Advisors Boris Djordjevic Founder & CEO Founder of 199 group, translating reprogramming science into the … gau Strategic Advisor Longevity entrepreneur and scientist; Oxford All-Innovate award winner. LinkedIn Email Dr. Avi Roy Strategic Advisor Oxford biomedical scientist; president of Biogerontology Research Foundation. LinkedIn Email Dr. Qinghua Lyu Chief Technical Officer Drug development expert; leads chemical sciences and senolytic programs. LinkedIn Email ZY Zico Yip Chief Operating Officer Operations lead across labs and manufacturing; fundraising and investments. LinkedIn
Instagram Instagram Log In Sign Up Close Never miss a post from biotechtvhq Sign up for Instagram to stay in the loop. Sign up Log in biotechtvhq Verified • Follow More options biotechtvhq Verified 15w 𝐌&𝐀 𝐍𝐞𝐰𝐬: Biotech woke up to a $2.5B acquisition this morning, the latest in a string of deals for commercial stage assets. Servier is buying Day One Biopharmaceuticals for $2.5 billion. Load more comments No comments yet. Start the conversation. Like 11 Comment Share Save March 6 Log in to like or comment. More posts from biotechtvhq Clip Clip Clip Clip Clip Clip Clip Clip Clip See mo
EDGAR Filing Documents for 0001213900-22-073323 This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser. SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home » Company Search » Current Page Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: SEC Accession No. 0001213900-22-073323 Filing Date 2022-11-17 Accepted 2022-11-17 09:00:15 Documents 30 Period of Report 2022-11-17 Document Format Files Seq Description Document Type Size 1
199 Biotechnologies - Engineering Human Longevity | Founded by Boris Djordjevic Skip to main content Home Programs Investors Company Contact Donate Home Contact Contact Contact Us Whether you are a researcher, investor, or potential partner, we would love to hear from you. Get in touch Email Use the contact form to reach our team. Locations United Kingdom / Singapore / Hong Kong Specialized inquiries Partnerships & Business Development Strategic partnerships, licensing opportunities, and business collaborations. Select "Partnership Opportunity" in the form. Research Collaboration
199-biotechnologies · GitHub Skip to content Navigation Menu Toggle navigation Sign in Appearance settings 199-biotechnologies Platform AI CODE CREATION GitHub Copilot Write better code with AI GitHub Copilot app Direct agents from issue to merge MCP Registry New Integrate external tools DEVELOPER WORKFLOWS Actions Automate any workflow Codespaces Instant dev environments Issues Plan and track work Code Review Manage code changes APPLICATION SECURITY GitHub Advanced Security Find and fix vulnerabilities Code security Secure your code as you build Secret protection Stop leaks before they start … Trust center Partners View all resources Open Source COMMUNITY GitHub Sponsors Fund open source developers PROGRAMS Security Lab Maintainer Community Accelerator GitHub Stars Archive Program REPOSITORIES Topics Trending Collections Enterprise ENTERPRISE SOLUTIONS Enterprise platform AI-powered developer platform AVAILABLE ADD-ONS GitHub Advanced Security Enterprise-grade security features Copilot for Business Enterprise-grade AI features Premium Support Enterprise-grade 24/7 … our input very seriously. Include my email address so I can be contacted Cancel Submit feedback Saved searches Use saved searches to filter your results more quickly --> Name Query To see all available qualifiers, see our documentation . Cancel Create saved search Sign in Sign up Appearance settings Resetting focus You signed in with another tab or window. Reload to refresh your session. You signed out in another tab or window. Reload to refresh your session. You switched acc
Instagram Instagram Log In Sign Up Close Never miss a post from phpagency Sign up for Instagram to stay in the loop. Sign up Log in phpagency • Follow More options phpagency 48w We’re thrilled to announce LMT Financial's partnership with Integrity! Join us in congratulating Jonathan Mason and his team as they continue to educate and empower their agents, their clientele, and their communities at large. . . . . #IntegrityPartnership #IntegrityFamily #PHPAgency #LMTFinancial #LifeInsurance Load more comments khloechelle 42w How many bodies u got A LOT Like Reply brandonebeal Verified 48w 👏
Pleiotropy and Disease Interactors: The Dual Nature of Genes Linking Ageing and Ageing-related Diseases | bioRxiv Skip to main content Home About Submit ALERTS / RSS Search for this keyword Advanced Search New Results Pleiotropy and Disease Interactors: The Dual Nature of Genes Linking Ageing and Ageing-related Diseases Gustavo Daniel Vega Magdaleno , View ORCID Profile Joao Pedro de Magalhaes doi: https://doi.org/10.1101/2024.05.20.594975 Gustavo Daniel Vega Magdaleno 1 Integrative Genomics of Ageing Group, Institute of Ageing and Chronic Disease, University of Liverpool , Liverpool L7 8TX, U … of Cancer ARDs 90 self-reported cancer diseases were retrieved from UK Biobank (Application 6342) using the field 20001 and all available visits per participant. We then selected those with an occurrence of at least 2000 cases, leaving 11 Cancers to analyse. The age-of-onset of these 11 cancers was then determined using the field 20007 (Interpolated age of participant when cancer occurred). For each cancer, we divided the number of cases at a specific age by the total number … f ARDs the gene indirectly interacts with. ARC- Pleiotropy and iARC-Interaction apply similarly but for ARCs. Since this work focuses mostly on ARCs, we use the term Pleiotropy as a synonym of ARC_ Pleiotropy . Download figure Open in new tab Figure 8. Pleiotropy and iARC_Interactors . A single gene can influence multiple ARDs or ARCs through either a direct association or indirect interaction. The intense green circle represents the reference gene, lighter green circles indi … is CSO of YouthBio Therapeutics, an advisor/consultant for the Longevity Vision Fund, 199 Biotechnologies, and NOVOS, and the founder of Magellan Science Ltd, a company providing consulting services in longevity science. Acknowledgments GDVM thanks his sister, Laura Sujei Vega Magdaleno, for her support in enhancing the quality of some of the explanatory figures in this work. References ↵ Altenhoff , A. M. , Škunca , N. , Glover , N. , Train , C. M. , Sueki , A. , Piližota , … 2019.00417 OpenUrl CrossRef White S , Medvedovic M ( 6 ). “KEGGlincs design and application: an R package for exploring relationships in biological pathways [version 1; not peer reviewed].” doi: 10.7490/f1000research.1113436.1 . OpenUrl CrossRef Wolfson , M. , Budovsky , A. , Tacutu , R. , & Fraifeld , V . ( 2009 ). The signaling hubs at the
%PDF-1.6 %���� 31926 0 obj >stream hޔ�ͮg7 �y���Ս�|J�H�B�U� bQ�h�hEj ��8Nr�{�X�nf���ω�$�� �9��.�ÕH����܅D��� /OI$H W�(R�bJ* ��pe'm���[��J^�qXD�.�k�lRk�`�-�-5�R�9�y�&�pa�Z+�"�V�%'�+ܐR�99���܂QD�й֊,��J쒮�/Į.��Y��B�uٓ�鲣06]`1�D�ED6�ы�&�{,���Zk��u�r4]t,�Q���LfA��|1\�E�,��ʰ�Zk�S+� �5��,a�"&�a1^���5�,f��q�{�X �Y��*��[���+b�C�@.AA/\]�����s� �{��*\�2�5����|a��Ȼ`�b��D��Ȅ�z�� ��*�*�͎w]6�xO�Zp���Q�Xf�� P �d�d��,3��,���W�d�~���r����\���:�� ��� @u�=�e���ح_��-vy ��.�}�%F�:�7p�[����~�$L��H'P� Y�WP$R �3�I�@tU�X��` /D��� �� 2�(GK�Qp��n�Yy?�u��Hb��5& … ac-902c8ae6fbe6 xmp.did:17FE61601D18E411B9079205F510BB05 default converted from application/x-indesign to application/pdf Adobe InDesign 20.2 (Windows) / 2025-11-10T15:32:23-05:00 application/pdf JCC 2025-2026 College Catalog Adobe PDF Library 17.0 False endstream endobj 703 0 obj > endobj 705 0 obj >/Metadata 702 0 R/Outlines 15459 0 R/Pages 652 0 R/StructTreeRoot 1084 0 R/Type/Catalog/ViewerPreferences >>> endobj 707 0 obj [/ICCBased 710 0 R] endobj 709 0 obj > endobj 710 0 … A�H��U�V}�a7�u^:�c�2�+M�Jm�3��6?�-N��)��ch{> ��S���?�߿��o� �1��_�������.1�RFp�,�(S��5�� �S�u�P� ���)�� ��� �ĺ�J��mxN5 tS�˯:���wv@����e��U��N���%��i'WԱ+�V�!P���U4����{�v,`Z��� o�L!�v��R�2�.�iH�'���#3��*���/�9;��@n��LV��M����$q�/����&���b��gErX�p{�?TP��� &~���-̈1�v����A�Ԃf�ݨH�r��[s����w^MD=+q�]? �/S我��-�M�Uz�>`�s�A�Q�F���6A�jlx�}����*�*��� rs����q| ����S��H����|0b�KEzA 3�:DZ\ +�Ӊ 5{�d�H��ܣ+��ʢZ�|�}q�N�S�t6o�͂fGؚB+�U� o�K7���+t&��R … ac-902c8ae6fbe6 xmp.did:17FE61601D18E411B9079205F510BB05 default converted from application/x-indesign to application/pdf Adobe InDesign 20.2 (Windows) / 2025-11-10T15:32:23-05:00 application/pdf JCC 2025-2026 College Catalog Adobe PDF Library 17.0 False endstream endobj 703 0 obj > endobj 32008 0 obj > endobj 32009 0 obj >stream H��Wko����_�� ���}/ Be�I[$�[ � ��B�h�7��+Ji��;�\�Ki��7�1ޝ93{��h��g���\]�����% ���$VDi%�2:�Lkb4�4e��:�?}M����i{ؓ���fJ.F�%˜�(���o�FH��\���ׇ�B … ac-902c8ae6fbe6 xmp.did:17FE61601D18E411B9079205F510BB05 default converted from application/x-indesign to application/pdf Adobe InDesign 20.2 (Windows) / 2025-11-10T15:32:23-05:00 application/pdf JCC 2025-2026 College Catalog Adobe PDF Library 17.0 False endstream endobj 703 0 obj > endobj 32151 0 obj >stream H��W�n9}�W�� ��d ��d3�ei��`��
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Instagram Instagram Log In Sign Up Close Never miss a post from thetonyholland Sign up for Instagram to stay in the loop. Sign up Log in thetonyholland Verified • Follow More options thetonyholland Verified 1d 🔥 What an incredible day with Everett Foney, Gaylan Hendricks, and Team Chicago! The energy, enthusiasm, and commitment to growth in the room were second to none. When you surround yourself with people who are hungry to learn, improve, and take their business to the next level, great things happen. 💎 Success is built by staying coachable, taking action, and showing up with the right at
%PDF-1.3 %��������� 5 0 obj > stream x��;��Hn���W(� F#�]��ؙ� �;v���z�?�� VI���kL�=�Io�"���ۿn���W�ڙ�����o�o���o��������z6U;K����~ go9���������?;��� B�o�Ib��_�1~�#�}�m;�~~ {: /���U�YL�e��؏�}������gﵟ}+�گԮ� �|�zn�����������\��?��%�i?m��}�� � �X�T0����g=Ɔ�{.y�io��X���ꀥ�}�F�Gi'�u =������~��m6��z~�R�ڠK#��uq�=�!��[�^�W�c��xaBr?����_��J�� I����/���Ϡ:����>� �*^�|c/W_��1�r���J|�{$�� ��K�Vc� 6�8��a\�:�"Y��N*%��w핼p ���P@�+bs9�� ?����s��� ���M��q:6HΪ��6�+[��#6ʘȏJLm �wG���e���8e�D�Dž� 7U��>$��r}�����-]��*5�u�[AЯVç�������#���� d/�P�J��̇���H�/�r#��ƍ�-ew����Az�NhO�� �NG�;���
SEC Filings | Gorilla Technology Overview Corporate Leadership Board of Directors Corporate Governance Stock Information News & Events Press Releases Events & Presentations Financials SEC Filings Quarterly Results Analyst Coverage Annual Reports Resources FAQs Whitepapers Videos Customer Success Email Alerts Contact IR SEC Filings SEC FILINGS Financial Integrity Complete Access to Our SEC Filings Email Alerts About Us Global Footprint Customer Service Partners Careers Whitepapers CSR Policy Contact IR Blog Follow Follow Follow © Gorilla Technology. All Rights Reserved. Privacy Policy
%PDF-1.7 %���� 6603 0 obj >stream ����_��|�]g�3�6W��k|��FM�Ne� '�c$_��ސ�X�c��Zq��H����E�:���S�B���Q�� �k��$�'��;@�j�"��d�UnXA^-]�n�'XM� f�7�b >stream \�F�ܔi����֖>T�,���j��D_d���"�k~�^Z�JS�����wP� w+�[!/�M�z�K���I7�{CU�Y�F.�0�:�Z_W�b�c���z�v��(9���L�a^az��I8ɐ��{�ג ���n|��$c��Hc|'>��������ߩCұޖ >stream ��d��*�/pd1 4� %��˟� Af�m��Q4t ��ji����b&��y=�������O-�ܡ���ˌp�v%V�0��rg�ǵ���\%e �� [~�'6C1�m/Ǯ����2-Y�U�v�˵wU/�BUR�ѩ)K[�}!���0�w�����k�r.p45Q�o"_*���r ~Z��u;��/G9�S.�v����;�2���D�� �7��������P�5�| �o���Z_[���� �C��|���Q��An��k� #��`Y*L O��ov��s-��=���O�l
EDGAR Entity Landing Page EDGAR | Company Search Results Disabled --> FAQ EDGAR search tools Feedback Classic version Home » Company Search This company's Exchange Act registration has been revoked This company's Exchange Act registration as a Municipal Advisor has been revoked This company's Exchange Act registration as a Municipal Advisor has been cancelled Investor toolkit: On [+] Company Information CIK: EIN: LEI: SIC: (CF Office: ) State location: State of incorporation: Fiscal year end: Business address: Phone: Mailing address: Category: Filings: EDGAR filings since Get insider transacti
Sponsors | ARDD2024 Main Past events ARDD 2025 ARDD 2024 XPRIZE Healthspan Team Summit 2024 ARDD 2023 ARDD 2022 About Speakers Speakers 2026 Speakers 2025 Speakers 2024 Speakers 2023 Speakers 2022 Program Main Track Longevity Medicine Track Emerging Science & Technologies Workshop Physics in Aging Biology Startup Pitch Replacement in Aging Workshop Molecular Nutrition Workshop ARDD Tracks Sponsorship Sponsorship Brochure Sponsors 2025 Sponsors 2024 Sponsors 2023 Sponsors 2022 Media Scam Warning Photos Videos Media Kit Photos 2025 Photos 2024 Photos 2023 Photos 2022 Vid
Partner | Biogen Disease Areas Alzheimer's Disease Amyotrophic Lateral Sclerosis Friedreich Ataxia Kidney Disease Lupus Multiple Sclerosis Postpartum Depression Spinal Muscular Atrophy Living with CLE, a form of lupus: Nandan's story Science & Innovation R&D Expertise Pipeline Clinical Trials Early Access Programs Making Medicines Safely & Reliably Our Scientists The power of representation in clinical trials: Shanelle's story Medicines Report a Side Effect Contact Us Responsibility Access and Health Equity Culture & Inclusion Environment The CoLab Reporting & P
GSK accelerates oligonucleotide platform and pipeline medicines with acquisition of Elsie Biotechnologies | GSK You are about to access GSK historic archived press release material retained as a corporate record. References to products or their uses may be out of date and not reflect current medical, safety or regulatory information. For clinical information, consult the approved national product label information (SmPC). Continue Cancel Skip to content Skip to search Behind the Science magazine Company Company Purpose, strategy and culture GSK at a glance History and heritage Board of Directo … opment and Supply (MDS) Genomic sciences Technology Early careers Early careers Application process Apprentice programmes Internships and placements Graduate programme Graduate programme Business operations Engineering Manufacturing & supply Commercial Research & development Digital & tech Manufacturing sciences & technology Post graduate opportunities Frequently asked questions Veterans Our global and regional hubs How we hire How we hire Fraudulent internet
Digitalis Ventures | News About People Human Health Animal Health News Notebook The Digitalis Group: Digitalis Ventures Digitalis Commons © 2026 Digitalis Ventures ALL NEWS LIFE SCIENCES NEWS HEALTH TECHNOLOGIES NEWS ANIMAL HEALTH NEWS DIGITALIS VENTURES NEWS Thank you! Your submission has been received! Oops! Something went wrong while submitting the form. VARDA 5.13.2026 A plan to make drugs in orbit is going commercial MIT TECHNOLOGY REVIEW > EPIBIOLOGICS 4.20.2026 EpiBiologics Doses First Patient with EPI-326 Bispecific Antibody in Global Phase 1 Study for EGFR-Driven Solid Tumors BIOSP … ANCE > ONC.AI 10.24.2024 Onc.AI Awarded $2 Million National Cancer Institute Grant to Advance AI-based Clinical Decision Support for Metastatic NSCLC BIOSPACE > Alpha-9 Oncology 10.23.2024 Alpha-9 Oncology Inc. Announces $175 Million Oversubscribed Series C Financing to Advance Robust Clinical Pipeline of Radiopharmaceuticals CNHI NEWS > TERRAY THERAPEUTICS 10.21.2024 Terray Therapeutics aims for the clinic by 2026 C&EN > TERRAY THERAPEUTICS 10.17.2024 Terray … genomes Nature Biotechnology > DIGITALIS VENTURES 10.25.2023 Mars Companion Fund to take bigger bets on petcare startups GLOBAL CORPORATE VENTURING > Native Pet 10.16.2023 Native Pet launches new all-in-one supplement Pet Food Processing > Faeth Therapeutics 10.13.2023 Faeth Therapeutics Announces National Academy of Medicine Recognition for Co-founder Dr. Siddhartha Mukherjee Business Wire > Eden Brew 10.11.2023 Eden Brew alternative milk startup attracts $25m i … Wire > DIGITALIS VENTURES 10.3.2023 Mars and Digitalis Ventures launch $300m Fund to improve the lives of pets… MARS > Terray Therapeutics 10.2023 A New Molecular Language for Generative AI in Small-Molecule Drug Discovery NVIDIA > GRO Biosciences 9.27.2023 GRO Biosciences Presents Preclinical Data on Two ProGly™ Programs for Non-Standard Amino Acid Therapies Business Wire > PetMedix 9.19.2023 More animal magic as Zoetis acquires PetMedix in Cambridge Business Wee … ces 4.11.2023 GRO Biosciences CEO, Daniel J. Mandell, PhD, Awarded 2023 Termeer Fellowship Business Wire > Switch Therapeutics 3.14.2023 Switch Therapeutics Raises $52M in Series A Funding FINSMES > Code Ocean 2.17.2023 Code Ocean Partners with Nature Portfolio to Launch the Open Science Library with Ready-to-Run Software from Authors in Na
Instagram Instagram Log In Sign Up Close Never miss a post from biotechtvhq Sign up for Instagram to stay in the loop. Sign up Log in biotechtvhq Verified • Follow More options biotechtvhq Verified 20w 𝐅𝐫𝐨𝐦 𝐍𝐘𝐒𝐄: Today we are in New York at the home of our sponsor, the NYSE, for its annual partnership day. If you are a biotech company looking to list this year (or beyond), please reach out to Johanna Grossman, PhD and learn how you can list at this iconic place. Load more comments No comments yet. Start the conversation. Like 12 Comment Share Save February 2 Log in to like or comment.
News and Events – Locust Walk Skip to content Locust Walk Home Who We Are How We Support Dealmaking Our Core Values Our History & Name Our Leadership Our Advisors Our Capabilities Sell-Side Strategic Dealmaking Asia Transactions NewCo Creation Specialty Pharma Our Insights Market Conditions White Papers Podcasts News and Events Our Transactions Our Careers Our Career Opportunities Working At Locust Walk Experienced Analysts Associates Our Impact Contact Us News and Events Menu Market Conditions White Papers Podcasts News and Events Fierce Biotech: Banyan BioInnovations puts down roo … isher Scientific (NYSE: TMO). CytoReason will use this investment to expand the application of its models into additional indications, grow its proprietary molecular and clinical data, and establish an office in Cambridge, Massachusetts later this year. Ascentage Pharma signs option agreement with Takeda to enter into exclusive global license for Olverembatinib June 24, 2024 Ascentage Pharma (6855 HK), a global biopharmaceutical company engaged in developing novel therapies f … used on Locust Walk ’s 2023 First Quarter Market Conditions Report, in which we apply the latest data to analyze current activities in the life sciences deal landscape. Each quarter, Locust Walk’s deal team compiles key statistics and trends showcasing what is happening in the global private and public capital markets and strategic partnering and M&A activity. Biotalk Episode 2: A Conversation with Andrew Allen – March 15th, 2023 Click Here for a full summary of the episo … used on Locust Walk ’s 2023 First Quarter Market Conditions Report, in which we apply the latest data to analyze current activities in the life sciences deal landscape. Each quarter, Locust Walk’s deal team compiles key statistics and trends showcasing what is happening in the global private and public capital markets and strategic partnering and M&A activity. Biotalk Episode 2: A Conversation with Andrew Allen – March 15th, 2023 Click Here for a full summary of the … used on Locust Walk ’s 2023 First Quarter Market Conditions Report, in which we apply the latest data to analyze current activities in the life sciences deal landscape. Each quarter, Locust Walk’s deal team compiles key statistics and trends showcasing what is happening in the global private and public capital markets and strategic partnering and
Longevity biotechnology: bridging AI, biomarkers, geroscience and clinical applications for healthy longevity | Aging Submit an Article Navigate Home Editorial Board Editorial Policies Current Volume Archive Scientific Integrity Publication Ethics Statements Interviews with Outstanding Authors Newsroom Sponsored Conferences Podcast Contact Special Collections Submit an Article Online ISSN: 1945-4589 Navigate Home Editorial Board Editorial Policies Current Volume Archive Scientific Integrity Publication Ethics Statements Interviews with Outstanding Authors Newsroom Sponsored Conferences Podcast … ific Meeting of the BSRA NOVA 2026 Recap Longevity & Aging Series 2025 EPIC Award Winner: Longevity & Aging Series Research Paper | Volume 16, Issue 20 | pp 12955 —12976 Longevity biotechnology: bridging AI, biomarkers, geroscience and clinical applications for healthy longevity Yu-Xuan Lyu 1 , Institute of Advanced Biotechnology and School of Medicine, Southern University of Science and Technology, Shenzhen, China 2 Max Planck Institute for Biology of Ageing, Cologne … University Medical Center, Rostock, Germany , Asif Bhatti 22 America's Frontier Fund, VA 23320, USA , Benjamin Yaden 23 Department of Biology, School of Science, Center for Developmental and Regenerative Biology, Indiana University - Purdue University Indianapolis, Indianapolis Indiana 46077, USA , Bente Klarlund Pedersen 24 Centre for Physical Activity Research, Rigshospitalet and University of Copenhagen, Denmark , Björn Schumacher 25 Institute for Genome Stability in … ales, Sydney, New South Wales, Australia , Mark Hamalainen 87 Longevity Biotech Fellowship, Longevity Acceleration Fund, Vitalism, SF Bay, CA 94101, USA , Maximilian Unfried 14 , Healthy Longevity Translational Research Program, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 88 Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117608, Singapore , Michael S. Ringel 89 Boston Consulting Group, … Biochemistry of the Romanian Academy, Bucharest, Romania 22 America's Frontier Fund, VA 23320, USA 23 Department of Biology, School of Science, Center for Developmental and Regenerative Biology, Indiana University - Purdue University Indianapolis, Indianapolis Indiana 46077, USA 24 Centre for Physical Activity Research, Rigshospitalet and Univer
199 Biotechnologies - Engineering Human Longevity | Founded by Boris Djordjevic Skip to main content Home Programs Investors Company Contact Donate Home Programs Platform Rewrite → Clear → Measure One platform, three rails: reprogram malignant behavior, clear senescence, and measure outcomes to guide decisions. Rewrite → Clear → Measure Three stages showing cell state rewriting, senescent cell clearance, and diagnostics readout. REWRITE CLEAR MEASURE 01 Cancer Reprogramming (E‑ON‑001) Rewrite malignant programs to force re‑differentiation, senescence, and natural apoptosis with safety‑first de
Skip to main content Fidelity.com Home Log in Accounts & Trade Portfolio Account Positions Trade Fidelity Trader+ Web Fidelity Trader+ Transfers Cash Management Bill Pay Full View ® Security Settings Account Features Documents Tax Forms & Information Retirement Distributions Refer a Friend Investing Self-Directed Investing Advanced Trading Investing for a Child Managing Cash & Credit Investment Accounts & Products Investing & Trading Education Retirement Retirement Planning 401(k) Rollovers & IRA Transfers Retirement Accounts Retirement Education Wealth Management Wealt … nsights » News » Print Share Share Mutual Funds and Mutual Fund Investing - Fidelity Investments Clicking a link will open a new window. Facebook Twitter LinkedIn Default text size A Larger text size A Largest text size A {{news.byLine}}, {{news.distributor}} - {{getTimeformat(news.publicationTime)}} mergers-and-acquisitions {{news.disclaimer}} close Send to (Separate multiple e-mail addresses with commas) Please enter a valid e-mail add
199 Biotechnologies - Engineering Human Longevity | Founded by Boris Djordjevic Skip to main content Home Programs Investors Company Contact Donate 199 Biotechnologies Reprogramming healthspan We build therapies that address cancer and aging at their common source - epigenetic damage. Instead of destroying cells, we redirect them back to healthier programs. Our Approach Explore Research We combine partial reprogramming, senolytic compounds, and low-cost diagnostics to extend healthy lifespan by decades - not just months. Translational research lab Lead Program Cancer Reprogramming Diagnostics
199 Biotechnologies - Engineering Human Longevity | Founded by Boris Djordjevic Skip to main content Home Programs Investors Company Contact Donate 199 Biotechnologies Reprogramming healthspan We build therapies that address cancer and aging at their common source - epigenetic damage. Instead of destroying cells, we redirect them back to healthier programs. Our Approach Explore Research We combine partial reprogramming, senolytic compounds, and low-cost diagnostics to extend healthy lifespan by decades - not just months. Translational research lab Lead Program Cancer Reprogramming Diagnostics
PE Weekly: Healthcare Tech, Services Come Back Into Focus | ACG Insights (Formerly Middle Market Growth) About Advertise Subscribe // ACG About Advertise Subscribe // ACG Magazines The Latest Multimedia Podcast Video Sectors Manufacturing and Industrials Technology Healthcare Consumer Products Food and Agriculture Business and Financial Services Next Target Deal Stage Business Development Due Diligence Deal Execution Value Creation Exit People 2026 BD Pros to Watch Home News & Trends Latest News PE Weekly: Healthcare Tech, Services Come Back Into Focus PE Weekly: Healthcare Tech, Services … l acquire the company. Fundraising 26North Raises $5.9 Billion for Inaugural PE Fund. 26North Partners announced the close of its inaugural private equity fund with $5.9 billion in capital commitments, surpassing its initial $4 billion target. The fund will focus on investments in middle- and upper-middle-market companies, and has already completed seven equity investments. Topspin Raises $328 Million for Consumer Investments. Topspin Consumer Partners, a private equity firm … umer Partners, a private equity firm focused on the consumer sector, closed its Fund III with $328 million in capital commitments. The firm said Fund III will continue to focus on investing in health and wellness, personal care, beauty, food and beverage, household goods, and pet, among other consumer-focused verticals. Middle Market Growth is produced by the Association for Corporate Growth. To learn more about the organization and how to become a member, visit www.ac
M&A News: Global M&A Deals Week of November 17 to 23, 2025 Skip to content M&A Trainings Close M&A Trainings Open M&A Trainings Programs International Mergers & Acquisitions Expert (IM&A) Certified Post Merger Integration Expert (CPMI) Mergers & Acquisitions Professional (M&AP) Legal Mergers & Acquisitions Expert (LM&A) HR Mergers & Acquisitions Expert (HRM&A) Certified Separation, Carve-Out and Divestment Expert (SCDE) Valuation Training with Prof. Aswath Damodaran In-house M&A Training Tailored to your needs, covering the full M&A lifecycle with flexible delivery options and cust
Speakers | ARDD 2023 Main Past events ARDD 2025 ARDD 2024 XPRIZE Healthspan Team Summit 2024 ARDD 2023 ARDD 2022 About Speakers Speakers 2026 Speakers 2025 Speakers 2024 Speakers 2023 Speakers 2022 Program Main Track Longevity Medicine Track Emerging Science & Technologies Workshop Physics in Aging Biology Startup Pitch Replacement in Aging Workshop Molecular Nutrition Workshop ARDD Tracks Sponsorship Sponsorship Brochure Sponsors 2025 Sponsors 2024 Sponsors 2023 Sponsors 2022 Media Scam Warning Photos Videos Media Kit Photos 2025 Photos 2024 Photos 2023 Photos 2022 Vi … drea Ablasser is recipient of the EMBO Gold Medal, the Dr. Josef Steiner Cancer Award, the Coley Award, the Sanofi-Institut Pasteur Award, the National Latsis Prize, the ACTERIA Prize, and the Eppendorf Award, and she is an elected member of EMBO and Leopoldina. She has been nominated "Highly Cited Researcher". She is the founding scientist of IFM Due, a biopharmaceutical company developing cGAS-STING antagonists for the treatment of inflammatory disorders. Victoria Acosta-Ro … the Head of the Hong Kong Office of Insilico Medicine. He is leading a team of application scientists in Hong Kong working on the AI-enabled biological target discovery platform - PandaOmics. His goal is to deliver the latest AI technology to scientists, medical doctors, biotechnology, and pharmaceutical companies around the world to help find actionable therapeutic targets, and accelerate drug discovery and development. Frank received his Ph.D. in biochemistry from the Hong … rsity of Pittsburgh. He is the national director of the Health and Aging Policy Fellowship (supported by the John A. Hartford Foundation, West Health Policy Institute and Atlantic Philanthropies) and previously directed national programs for the Robert Wood Johnson and MacArthur Foundations. Earlier, Dr. Pincus was deputy medical director of the American Psychiatric Association (APA) and founding director of APA's Office of Research, was the special assistant to the director … a University Medical Center and the 2017 recipient of the C. Charles Burlingame Award by the Institute of Living for contributions to the field of psychiatry and has received the William C. Menninger Memorial Award of the American College of Physicians for distinguished contributions to the science of mental health, the Research Mentorship Award
How much can we... - NUS Yong Loo Lin School of Medicine Facebook Log In NUS Yong Loo Lin School of Medicine's Post NUS Yong Loo Lin School of Medicine November 5, 2024 · Shared with Public How much can we manage #ageing with #biotechnology ? Find out at the #HealthyLongevity webinar this Nov 7 with Professor Boris Djordjevic, founder of 199 Biotechnologies. Together with host Professor Andrea Maier, ( #NUSMedicine ), we’ll be unpacking the secrets of partial cellular reprogramming for battling diseases and the symptoms of ageing itself, as we explore the question: what’s the future of li
United Kingdom Biotech Pharma & Medical Device Companies - Career Pages About Directory Promoted Listings Purchase Data Drug Pipelines Data Licensing Weekly Update Newsletter Contact United Kingdom - Biotech, Pharma & Life Science Companies - Career Pages UK - Glasgow Curia (formerly AMRI) is a CRO/CDMO providing discovery, development, drug substance and drug product manufacturing for small molecules and biologics across 20 global sites. UK - Stirling Symbiosis is an FDA-inspected and MHRA-licensed specialist sterile GMP manufacturer of biopharmaceuticals for clinical trials and
GitHub - 199-biotechnologies/clinic-starter: Minimalist medical clinic website starter with Steve Jobs design philosophy · GitHub Skip to content Navigation Menu Toggle navigation Sign in Appearance settings Platform AI CODE CREATION GitHub Copilot Write better code with AI GitHub Copilot app Direct agents from issue to merge MCP Registry New Integrate external tools DEVELOPER WORKFLOWS Actions Automate any workflow Codespaces Instant dev environments Issues Plan and track work Code Review Manage code changes APPLICATION SECURITY GitHub Advanced Security Find and fix vulnerabilities Code secur … Trust center Partners View all resources Open Source COMMUNITY GitHub Sponsors Fund open source developers PROGRAMS Security Lab Maintainer Community Accelerator GitHub Stars Archive Program REPOSITORIES Topics Trending Collections Enterprise ENTERPRISE SOLUTIONS Enterprise platform AI-powered developer platform AVAILABLE ADD-ONS GitHub Advanced Security Enterprise-grade security features Copilot for Business Enterprise-grade AI features Premium Support Enterprise-grade 24/7 … our input very seriously. Include my email address so I can be contacted Cancel Submit feedback Saved searches Use saved searches to filter your results more quickly --> Name Query To see all available qualifiers, see our documentation . Cancel Create saved search Sign in Sign up Appearance settings Resetting focus You signed in with another tab or window. Reload to refresh your session. You signed out in another tab or window. Reload to refresh your session. You switched acc
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
2024 Attendees — WellFounded - Founders Health & Concierge Performance Medicine | CHHP Longevity Research 0 Skip to Content Home CURIA Concierge Founders Health Founders Health & Performance Programme Clients Deck Leaders in Health Leaders in Health Summit 2026 LiH Awards Experiences All Events Articles & Research Articles, Insights & Essays CHHP Research Institute TALK TO US Open Menu Close Menu TALK TO US Home CURIA Concierge Founders Health Founders Health & Performance Programme Clients Deck Leaders in Health Leaders in Health Summit 2026 LiH Awards Experiences Al … ess; Alice Byram - NoBACZ; Alina Topf - New Work Targets; Amy Nelson - Clinical Fellowship Guy's and St Thomas' NHS Trust; Andrea Gartenbach - Art of Longevity Clinic; Andrew Crockett - WellFounded; Andrew Elder - Albion VC; Andrew Thomas - Adoreum Club; Andy D Franklyn-Miller - Nuritas; Angus Perry - GP & General Practice.AI Founder; Anna Koprivc - New Work Targets; Anna Lippett - Doctify; Anne Bruinvels - Px HealthCare; Anne Fleischer - Novo Nordisk; Anne Margaret Glove
199 Biotechnologies - Engineering Human Longevity | Founded by Boris Djordjevic Skip to main content Home Programs Investors Company Contact Donate Home Investors Investors Rewrite disease. Measure outcomes. We reprogram malignant and senescent cells, then prove the change with real‑time diagnostics and transparent milestones. Rewrite → Clear → Measure Three stages showing cell state rewriting, senescent cell clearance, and diagnostics readout. REWRITE CLEAR MEASURE 70% E-ON-001 progress Preclinical in-vivo efficacy towards GBM readouts -90% Diagnostics cost AgeQuant vs traditional lab workflo
199 Biotechnologies - Engineering Human Longevity | Founded by Boris Djordjevic Skip to main content Home Programs Investors Company Contact Donate Home Donate Donate Donate to 199 Bio Your donation funds work in epigenetic reprogramming, NAD+ diagnostics, and polyphenol therapeutics. One-time Supporter $25 Donate Contributor $50 Donate Patron $100 Donate Any Amount Custom Donate Monthly Friend $10/mo Donate Partner $25/mo Donate Founder $100/mo Donate Cryptocurrency Bitcoin Show Ethereum Show Engineering human longevity through partial reprogramming, polyphenols research, and advanced diagnos
199 Biotechnologies - Engineering Human Longevity | Founded by Boris Djordjevic Skip to main content Home Programs Investors Company Contact Donate Home Company Company About 199 Bio We are the reprogramming company: rewriting malignant and senescent cell behavior and measuring outcomes with real‑time diagnostics. Mission Make disease biology legible and reversible. We build therapies that reprogram malignant and senescent cell states while using diagnostics to verify change. Team & Advisors Boris Djordjevic Founder & CEO Founder of 199 group, translating reprogramming science into the … gau Strategic Advisor Longevity entrepreneur and scientist; Oxford All-Innovate award winner. LinkedIn Email Dr. Avi Roy Strategic Advisor Oxford biomedical scientist; president of Biogerontology Research Foundation. LinkedIn Email Dr. Qinghua Lyu Chief Technical Officer Drug development expert; leads chemical sciences and senolytic programs. LinkedIn Email ZY Zico Yip Chief Operating Officer Operations lead across labs and manufacturing; fundraising and investments. LinkedIn
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC